BR0314081A - Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase - Google Patents

Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase

Info

Publication number
BR0314081A
BR0314081A BR0314081-4A BR0314081A BR0314081A BR 0314081 A BR0314081 A BR 0314081A BR 0314081 A BR0314081 A BR 0314081A BR 0314081 A BR0314081 A BR 0314081A
Authority
BR
Brazil
Prior art keywords
bisphosphonate
hmg
coa reductase
reductase inhibitor
combination therapy
Prior art date
Application number
BR0314081-4A
Other languages
English (en)
Inventor
Cindy Maree Baulch-Brown
Andrew Spencer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0314081A publication Critical patent/BR0314081A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

"TERAPIA DE COMBINAçãO COMPREENDENDO UM BISFOSFONATO E UM INIBIDOR DE HMG-COA REDUTASE". A presente invenção refere-se a uma composição farmacêutica para o tratamento de malignidades, em particular mieloma múltiplo (MM), compreende em combinação um bisfosfonato, por exemplo, ácido zoledrónico ou um sal ou éster, e um inibidor de HMG-CoA redutase para emprego simultâneo, seq³encial ou separado. Também fornecido, é um método de tratar um paciente sofrendo de uma doença maligna compreendendo administrar ao paciente uma quantidade eficaz de um bisfosfonato e uma quantidade eficaz de um inibidor de HMG-CoA redutase.
BR0314081-4A 2002-09-09 2003-09-08 Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase BR0314081A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220885.8A GB0220885D0 (en) 2002-09-09 2002-09-09 Organic compounds
PCT/EP2003/009972 WO2004024165A1 (en) 2002-09-09 2003-09-08 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor

Publications (1)

Publication Number Publication Date
BR0314081A true BR0314081A (pt) 2005-07-05

Family

ID=9943733

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314081-4A BR0314081A (pt) 2002-09-09 2003-09-08 Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase

Country Status (10)

Country Link
US (2) US20060234985A1 (pt)
EP (1) EP1539186A1 (pt)
JP (1) JP2006500401A (pt)
CN (1) CN1327844C (pt)
AU (1) AU2003270154A1 (pt)
BR (1) BR0314081A (pt)
CA (1) CA2497182A1 (pt)
GB (1) GB0220885D0 (pt)
HK (1) HK1080734A1 (pt)
WO (1) WO2004024165A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327742D0 (en) * 2003-11-28 2003-12-31 Isis Innovation Novel uses of known drugs
EP1802641B8 (en) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2007109585A2 (en) 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
WO2008128056A1 (en) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AU2008353145B2 (en) * 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
ES2339524B1 (es) * 2008-08-28 2011-03-22 Proyecto De Biomedicina Cima, S.L. Nuevo biomarcador como diana terapeutica en cancer de pulmon.
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011097563A1 (en) * 2010-02-08 2011-08-11 Board Of Regents Of The University Of Nebraska Biomineral and metal binding liposomes, their synthesis, and methods of use thereof
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
EP1061917A1 (en) * 1998-03-13 2000-12-27 Merck & Co., Inc. Methods of inhibiting bone resorption
US20010025028A1 (en) * 1998-03-13 2001-09-27 Merck & Co., Inc. Methods of inhibiting bone resorption
YU68900A (sh) * 1998-05-12 2002-12-10 Warner-Lambert Company Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
WO2002028270A2 (en) * 2000-10-06 2002-04-11 Probiochem, Llc The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor

Also Published As

Publication number Publication date
EP1539186A1 (en) 2005-06-15
JP2006500401A (ja) 2006-01-05
HK1080734A1 (en) 2006-05-04
US20090209493A1 (en) 2009-08-20
CA2497182A1 (en) 2004-03-25
US20060234985A1 (en) 2006-10-19
CN1681515A (zh) 2005-10-12
GB0220885D0 (en) 2002-10-16
CN1327844C (zh) 2007-07-25
AU2003270154A1 (en) 2004-04-30
WO2004024165A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR0115696A (pt) Uso de bisfosfonatos para tratamento de dor
MD960307A (ro) Compoziţii farmaceutice cu conţinut de acid hialuronic, utilizarea compoziţiilor pentru tratamentul bolilor pielii, metodă de tratament al bolilor pielii
ATE285760T1 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
IL168365A (en) Use of a rasagaline with or without riluzole for preparing a medicament for treating amyotrophic lateral sclerosis
BR0017075A (pt) Derivados de piridopirimidinona para tratamento de doença neurodegenerativa
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
BRPI0308663B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
WO2002000227A8 (en) Use of lanthanum compounds for the treatment of bone diseases
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ATE520691T1 (de) Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
BR0311613A (pt) Métodos para inibição, tratamento ou prevenção de sintomas de atrofia da pele, ou atrofia epitelial ou da mucosa nas mulheres e utilização de composto
BR9910095A (pt) Compostos inibidores de spla2 para tratamento de doença
BR0315374A (pt) Compostos orgânicos
BR0015121A (pt) Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação
MA27157A1 (fr) Methode de traitement d'affections osseuses.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.